AstraZeneca Makes Major Commitment to Help Patients with Acute Coronary Syndrome Have BRILINTA (ticagrelor) Available in Their

  AstraZeneca Makes Major Commitment to Help Patients with Acute Coronary
  Syndrome Have BRILINTA (ticagrelor) Available in Their Local Communities

   Agreements with National, Regional and Independent Pharmacies Represent
  Greater Consistency to Help With Continuity of Care as Patients Transition
                            from Hospital to Home

Business Wire

WILMINGTON, Del. -- December 04, 2012

AstraZeneca (NYSE: AZN) today announced a new program with more than 26,000
national, regional and independent pharmacies to broaden stocking of
BRILINTA^® (ticagrelor) tablets, greatly enhancing its retail availability in
the United States. This new pharmacy program is another investment by
AstraZeneca to help patients with acute coronary syndrome (ACS) and healthcare
providers maintain continuity of care throughout the course of treatment.
AstraZeneca is working with payers as well as pharmacies to assist patients in
filling their prescriptions for BRILINTA in a timely manner once they leave
the hospital.

Participating pharmacy chains in this unique program include Walmart, Rite
Aid, Kmart, Sam’s Club, Publix, Kerr Drug, Wegmans, Giant Eagle, Tops Markets,
Kinney Drug, Bartell Drug, Bi-Lo, and Winn-Dixie. These participating retail
chains are not exclusive distributors and BRILINTA may be available at other
retail pharmacy chains and independent pharmacies. For additional information,
please call 1-888-512-7454 (1-888-51-BRILINTA).

“Our pharmacy program is one of many initiatives we have in place to help
ensure that patients with ACS have widespread access to BRILINTA, an important
medication indicated to reduce their risk for thrombotic cardiovascular
events,” said James Ferguson, MD, Executive Director, Medical Affairs and
Strategic Development, U.S., and Vice President for Global Medical Affairs at
AstraZeneca. “When a treating physician prescribes BRILINTA, it is critical
that their patients start and finish the entire course of treatment without
unnecessary disruptions, particularly when transitioning from the hospital to
home. We believe this program will truly help patients to get access to a
medication that is now part of multiple guidelines' recommended treatment
following an ACS event.”

“Our efforts to help improve continuity of care are important for patients
prescribed BRILINTA and pharmacies are key partners for us,” said Suzanne
Delaney, Executive Director, Commercial Brand Leader at AstraZeneca.“It’s
gratifying for us to see such robust support from wholesalers, retailers and
payers, indicating positive momentum in the market.”

BRILINTA is indicated to reduce the rate of thrombotic cardiovascular (CV)
events in patients with ACS (unstable angina [UA], non–ST-elevation myocardial
infarction [NSTEMI], or ST-elevation myocardial infarction [STEMI]). In PLATO,
BRILINTA has been shown to reduce the rate of a combined end point of CV
death, myocardial infarction (MI), or stroke compared to clopidogrel. In
PLATO, the difference between treatments was driven by CV death and MI with no
difference in stroke. In patients treated with an artery-opening procedure
known as percutaneous coronary intervention (PCI), BRILINTA reduces the rate
of stent thrombosis.

BRILINTA has been studied in ACS in combination with aspirin. Maintenance
doses of aspirin above 100 mg decreased the effectiveness of BRILINTA. Avoid
maintenance doses of aspirin above 100 mg daily.

BRILINTA payer access continues to grow, with more than 100 leading U.S.
payers providing “preferred” access to this medication. Overall, access is
currently 82% of covered lives with 70% having unrestricted access. In
addition, BRILINTA is now on formulary at 81% (324) of the top 400 hospitals
throughout the United States as identified by AstraZeneca. A full list of
available formularies that include BRILINTA can be found on Fingertip
Formulary, a website that offers formulary drug status on the most commonly
prescribed drugs across a comprehensive list of health plans.

Another important support resource now available is Access My BRILINTA, which
provides time-saving prescription access and affordability information to
patients and healthcare providers. Access My BRILINTA is available by calling
1-888-512-7454 (1-888-51-BRILINTA) or visiting

For patients that require BRILINTA beyond their hospital stay, a savings card
program is available based on eligibility. Commercially insured and
cash-paying patients may be eligible for one free 30-day prescription and can
save up to $825 per year on their next 11 refills. For each refill (a 30-day
supply of up to 60 tablets), savings may apply after the first $18 spent by a
patient, up to a $75 savings limit. Patients covered through Medicare,
Medicaid or similar federal or state programs may be eligible for one month
free prescription. Patients can find out more at
or by calling 1-888-412-7454.



  *BRILINTA, like other antiplatelet agents, can cause significant, sometimes
    fatal, bleeding
  *Do not use BRILINTA in patients with active pathological bleeding or a
    history of intracranial hemorrhage
  *Do not start BRILINTA in patients planned to undergo urgent coronary
    artery bypass graft surgery (CABG). When possible, discontinue BRILINTA at
    least 5 days prior to any surgery
  *Suspect bleeding in any patient who is hypotensive and has recently
    undergone coronary angiography, percutaneous coronary intervention (PCI),
    CABG, or other surgical procedures in the setting of BRILINTA
  *If possible, manage bleeding without discontinuing BRILINTA. Stopping
    BRILINTA increases the risk of subsequent cardiovascular events


  *Maintenance doses of aspirin above 100 mg reduce the effectiveness of
    BRILINTA and should be avoided. After any initial dose, use with aspirin
    75 mg - 100 mg per day


BRILINTA is contraindicated in patients with a history of intracranial
hemorrhage and active pathological bleeding such as peptic ulcer or
intracranial hemorrhage. BRILINTA is also contraindicated in patients with
severe hepatic impairment because of a probable increase in exposure; it has
not been studied in these patients. Severe hepatic impairment increases the
risk of bleeding because of reduced synthesis of coagulation proteins.


  *Moderate Hepatic Impairment: Consider the risks and benefits of treatment,
    noting the probable increase in exposure to ticagrelor
  *Premature discontinuation increases the risk of MI, stent thrombosis, and
  *Dyspnea was reported in 14% of patients treated with BRILINTA and in 8% of
    patients taking clopidogrel. Dyspnea resulting from BRILINTA is
    self-limiting. Rule out other causes
  *BRILINTA is metabolized by CYP3A4/5. Avoid use with strong CYP3A
    inhibitors and potent CYP3A inducers. Avoid simvastatin and lovastatin
    doses >40 mg
  *Monitor digoxin levels with initiation of, or any change in, BRILINTA


  *The most commonly observed adverse reactions associated with the use of
    BRILINTA vs clopidogrel were Total Major Bleeding (11.6% vs 11.2%) and
    dyspnea (14% vs 8%)
  *In clinical studies, BRILINTA has been shown to increase the occurrence of
    Holter-detected bradyarrhythmias. PLATO excluded patients at increased
    risk of bradycardic events. Consider the risks and benefits of treatment

Please read full Prescribing Information, including Boxed WARNINGS, and
Medication Guide. This  information can be found  at

You are encouraged to report negative side effects of prescription drugs to
the FDA. Visit

AstraZeneca also offers a US patient assistance program for BRILINTA through
its AZ&ME^TM Prescription Savings Program. To determine eligibility, patients
can visit or call 1-800-AZandMe (292-6363).

                                   – ENDS –


"Preferred" formulary status means placement of BRILINTA on Tier 2 or the
formulary tier designated by the managed care organization as having the
lowest co-pay for branded products.

About BRILINTA^® (ticagrelor) tablets

BRILINTA is an oral antiplatelet treatment for ACS. BRILINTA is a
direct-acting P2Y[12] receptor antagonist in a chemical class called
cyclopentyltriazolopyrimidines (CPTPs). BRILINTA works by inhibiting platelet
activation and has been shown to reduce the rate of thrombotic CV events, such
as a heart attack or CV death, in patients with ACS.

BRILINTA is available in 90-mg tablets to be administered with a single 180-mg
oral loading dose (two 90-mg tablets) followed by a twice daily, 90-mg
maintenance dose. Following an initial loading dose of aspirin, BRILINTA
should be used with a maintenance dose of 75 mg - 100 mg aspirin once daily,
81-mg aspirin dose in the US.

BRILINTA is a registered trademark of the AstraZeneca group of companies.


PLATO (PLATelet Inhibition and Patient Outcomes) was a large (18,624 patients
in 43 countries), head-to-head patient outcomes study of BRILINTA vs
clopidogrel, both given in combination with aspirin and other standard
therapy. The study was designed to establish whether BRILINTA could achieve a
clinically meaningful reduction in cardiovascular (CV) events in acute
coronary syndrome (ACS) patients, above and beyond that afforded by
clopidogrel. Patients were treated for at least 6 months and up to 12 months.

PLATO demonstrated that treatment with BRILINTA led to a significantly greater
reduction in the primary end point – a composite of CV death, MI, or stroke –
compared to patients who received clopidogrel (9.8% vs 11.7% at 12 months;
1.9% absolute risk reduction [ARR]; 16% relative risk reduction [RRR]; 95% CI,
0.77 to 0.92; P<0.001). The difference in treatments was driven by CV death
and MI with no difference in stroke. In PLATO, the absolute difference in
treatment benefit vs clopidogrel was seen at 30 days and the Kaplan-Meier
survival curves continued to diverge throughout the 12-month treatment period.

The PLATO study also demonstrated that treatment with BRILINTA for 12 months
was associated with a 21% RRR in CV death (4% vs 5.1%; 1.1% ARR; P=0.001) and
a 16% RRR in MI compared to clopidogrel at 12 months (5.8% vs 6.9%; 1.1% ARR;

The primary safety end point in the PLATO study was Total Major Bleeding
(11.6% for BRILINTA and 11.2% for clopidogrel). In PLATO, non-CABG major +
minor bleeding events were more common with BRILINTA vs clopidogrel (8.7% vs
7% respectively). The rate of non-CABG-related major bleeding was higher for
BRILINTA (4.5%) vs clopidogrel (3.8%).

Dyspnea was reported in 14% of patients treated with BRILINTA and in 8% of
patients treated with clopidogrel. Dyspnea was usually mild to moderate in
intensity and often resolved during continued treatment.

About Acute Coronary Syndrome (ACS)

ACS is an umbrella term for conditions that result from insufficient blood
supply to the heart muscle. These conditions range from unstable angina (UA),
non–ST-elevation myocardial infarction (NSTEMI), or ST-elevation myocardial
infarction (STEMI).

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a
primary focus on the discovery, development and commercialization of
prescription medicines for gastrointestinal, cardiovascular, neuroscience,
respiratory and inflammation, oncology and infectious disease. AstraZeneca
operates in over 100 countries and its innovative medicines are used by
millions of patients worldwide.

For more information about AstraZeneca in the US or our AZ&Me™ Prescription
Savings programs, please visit: or call 1-800-AZandMe

2219801 11/12


Media Inquiries US
Stephanie Jacobson +1 302 885 5924 mob: +1 302 379 0443
Julia Walker +1 302 885 5172 mob: +1 610 350 8240
Investor Inquiries US
Ed Seage +1 302 886 4065 mob: +1 302 373 1361
Press spacebar to pause and continue. Press esc to stop.